Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lack of evidence for polymorphism in metoprolol metabolism.

Literature DB >> 6615692

Lack of evidence for polymorphism in metoprolol metabolism.

Abstract

The claim for polymorphism in the metabolism of metoprolol is based on a logical fallacy. A frequency distribution of metoprolol AUC data is presented and, although highly skewed, no evidence of more than a single population is apparent. Plasma and urine metoprolol and metabolite data are also presented to support this.

Entities: Chemical

Mesh：

Substances：

Year: 1983 PMID： 6615692 PMCID： PMC1427977 DOI： 10.1111/j.1365-2125.1983.tb04984.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

16 in total

1. Polymorphism of carbon oxidation of drugs and clinical implications.

Authors: T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal: Br Med J Date: 1978-09-02

2. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors: C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1975

3. Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors: K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1975

4. Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors: A Melander; K Danielson; B Scherstén; E Wåhlin
Journal: Clin Pharmacol Ther Date: 1977-07 Impact factor: 6.875

5. Plasma metoprolol concentrations in young, old and hypertensive subjects.

Authors: M J Kendall; D Brown; R A Yates
Journal: Br J Clin Pharmacol Date: 1977-08 Impact factor: 4.335

6. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Authors: C P Quaterman; M J Kendall; P G Welling
Journal: Eur J Clin Pharmacol Date: 1979-03-26 Impact factor: 2.953

Review 7. Clinical pharmacokinetics of metoprolol.

Authors: C G Regårdh; G Johnsson
Journal: Clin Pharmacokinet Date: 1980 Nov-Dec Impact factor: 6.447

8. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors: M J Kendall; V A John; C P Quarterman; P G Welling
Journal: Eur J Clin Pharmacol Date: 1980-02 Impact factor: 2.953

Review 9. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors: A Ebihara; A Fujimura
Journal: Clin Pharmacokinet Date: 1991-11 Impact factor: 6.447

Review 10. Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors: D W Clark
Journal: Drugs Date: 1985-04 Impact factor: 9.546

Lack of evidence for polymorphism in metoprolol metabolism.

1. Polymorphism of carbon oxidation of drugs and clinical implications.

2. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

3. Metabolism of metoprolol-(3-h) in man, the dog and the rat.

4. Enhancement of the bioavailability of propranolol and metoprolol by food.

5. Plasma metoprolol concentrations in young, old and hypertensive subjects.

6. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Review 7. Clinical pharmacokinetics of metoprolol.

8. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

9. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

10. The effect of age on the pharmacokinetics of metoprolol and its metabolites.

1. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Review 2. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

3. Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution.

4. Variability of plasma drug concentrations: some observations.

5. Variability of plasma drug concentrations--a reply.

6. Protecting the poor metaboliser--from what?

7. Interindividual variations in metoprolol metabolism--some clinical and other observations.

8. Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.

Review 9. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Review 10. Genetically determined variability in acetylation and oxidation. Therapeutic implications.